<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984083</url>
  </required_header>
  <id_info>
    <org_study_id>Prophylactic Vitamin K</org_study_id>
    <nct_id>NCT04984083</nct_id>
  </id_info>
  <brief_title>Maternal and Neonatal Benefits of Prophylactic Administration of Vitamin K Before Elective Cesarean Section</brief_title>
  <official_title>Maternal and Neonatal Benefits of Prophylactic Administration of Vitamin K Before Elective Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Centre, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculty of Medicine, Minia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Centre, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin K deficiency can cause serious risks to pregnant women and their babies that may lead&#xD;
      to hemorrhage, especially in newborns. We aim to evaluate the efficacy of vitamin k in&#xD;
      decreasing blood loss during and after elective cesarean section (CS), and to assess the&#xD;
      neonatal beneficial effects of prophylactic maternal vitamin k administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss (measured in cc)</measure>
    <time_frame>During Cesarean Section</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin time of the mother (measured in seconds)</measure>
    <time_frame>6 hour postmartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated Partial Thromboplastin Time (APTT) of the mother (measured in seconds)</measure>
    <time_frame>6 hour postmartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin Concentration (PC) of the mother (measured in %)</measure>
    <time_frame>6 hour postmartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin time of the newborn (measured in seconds)</measure>
    <time_frame>immediately after birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin Concentration (PC) of the newborn (measured in %)</measure>
    <time_frame>immediately after birth</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vitamin K</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will not take vitamin k before cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin k</intervention_name>
    <description>patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 20-40 years.&#xD;
&#xD;
          2. Gestational age between 36-39 weeks.&#xD;
&#xD;
          3. Patients who will undergo an elective cesarean section.&#xD;
&#xD;
          4. Full-term alive baby.&#xD;
&#xD;
          5. Non-scarred uterus.&#xD;
&#xD;
          6. No obstetric or medical complications.&#xD;
&#xD;
          7. No bleeding tendency.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients at less than 36 gestational weeks.&#xD;
&#xD;
          2. Patient refusal.&#xD;
&#xD;
          3. Patients who have thrombo-embolic complications.&#xD;
&#xD;
          4. Patients with obstetric and medical complications.&#xD;
&#xD;
          5. Patients with anomalous fetuses.&#xD;
&#xD;
          6. Patients on anti-coagulant drugs, long-term antibiotics, and anti-epileptic drugs.&#xD;
&#xD;
          7. Patients with obstetric cholestasis.&#xD;
&#xD;
          8. Patients with a previous history of preterm labor.&#xD;
&#xD;
          9. Patients with multiple pregnancies.&#xD;
&#xD;
         10. Gestational hypertension or preeclampsia.&#xD;
&#xD;
         11. Blood clotting disorders.&#xD;
&#xD;
         12. Placental abnormalities such as, Placenta accreta, Placenta increta, and Placenta&#xD;
             percreta.&#xD;
&#xD;
         13. Placental abruption and Placenta previa.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Research Centre</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Centre, Egypt</investigator_affiliation>
    <investigator_full_name>Mazen Abdel Rasheed</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

